Terms: = Prostate cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Prognosis
5 results:
1. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
[TBL] [Abstract] [Full Text] [Related]
3. Blood-based gene expression profiling in castrate-resistant prostate cancer.
Gross ME
BMC Med; 2015 Sep; 13():219. PubMed ID: 26365516
[TBL] [Abstract] [Full Text] [Related]
4. Frequency of tert Promoter Mutations in prostate cancer.
Stoehr R; Taubert H; Zinnall U; Giedl J; Gaisa NT; Burger M; Ruemmele P; Hurst CD; Knowles MA; Wullich B; Hartmann A
Pathobiology; 2015; 82(2):53-7. PubMed ID: 25997473
[TBL] [Abstract] [Full Text] [Related]
5. Combined analysis of TMPRSS2-ERG and tert for improved prognosis of biochemical recurrence in prostate cancer.
Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
[TBL] [Abstract] [Full Text] [Related]
